Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Are aerosols traveling as much as 30 feet in poorly ventilated environments? As early as July 6, 2020, studies “have demonstrated beyond any reasonable doubt that viruses are…
A recent study published in Cell Communication and Signaling presents evidence that cancer treatments that utilize adenoviruses for targeted treatment delivery may trigger additional glioma stem cell formation…
Alessia Cavazza, PhD, of Great Ormond Street Institute of Child Health (ICH) at University College London, discusses her research related to the potential of emerging gene-editing technologies, particularly…
The National Cancer Institute has developed a cloud-based infrastructure, the Cancer Research Data Commons, which allows cancer researchers to access, share, and analyze data from a centralized location,…
David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, explains that while PD-1 blockade and immune therapies have been…
Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer…
Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, discusses the limited treatment options for non-small cell lung cancer (NSCLC) patients without…
Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition.…
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, reports recent findings from a study using pembrolizumab and lenvatinib as a second-line treatment for clear cell…
Suresh Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, addresses autoimmune toxicities associated with combination immune therapies as in the CheckMate-227 trial for non-small cell…
